🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "major milestone" in the fight against increasingly resistant strains of the infection, according to health experts.

An International Public Health Issue

Cases of gonorrhoea are escalating globally, with figures suggesting over 82 million instances annually. Especially elevated rates are reported in Africa and countries within the WHO's designated area, which includes Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely advancement in the reality of rising global incidence, escalating drug resistance and the very limited therapeutic options presently on offer.”

Medical experts are deeply concerned about the rise in drug-resistant strains. The World Health Organization has designated it as a "critical concern". A tracking program showed that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Therapies Gain Authorization

One new antibiotic, also known as a brand name, was authorized by the US FDA in recent days for use against gonorrhoea. This STI can lead to significant complications, including infertility. Scientists believe that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GSK, was also approved in the same week. This treatment, which is employed against UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This milestone signifies a major breakthrough in the management of highly resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Data and Worldwide Availability

As per data released by a major medical journal, zoliflodacin eradicated over nine in ten of cases of the STI. This puts it on an equal footing with the typical regimen, which involves a dual-drug approach. The research enrolled nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Doctors directly involved have voiced optimism. Access to a single-dose, oral treatment like this is described as a "revolutionary step" for public health efforts. This is considered crucial to lessen the impact of the infection for people and to halt the transmission of highly drug-resistant gonorrhoea worldwide.